Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome).
M O Savage(St Bartholomew's Hospital), R G Rosenfeld(Laboratório Interinstitucional de e-Astronomia), Pierre Chatelain(Hôpital Edouard Herriot), M A Preece(St Bartholomew's Hospital), M C Postel-Vinay(Hôpital Necker-Enfants Malades), Kerstin Hall(Children's Hospital of Orange County), MB Ranke(St Bartholomew's Hospital), Andrew Cotterill(The University of Queensland), Werner Blum(University of Kassel)
Cited by 203
Related Papers
Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition
|Journal of Biological Chemistry|1993|477
Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease
|Journal of Endocrinology|1994|271
X-linked acrogigantism syndrome: clinical profile and therapeutic responses
|Endocrine Related Cancer|2015|186
Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth.
|Molecular Endocrinology|1993|160
Long-Term Treatment of Growth Hormone Insensitivity Syndrome with IGF-I
|Hormone Research in Paediatrics|1999|117